PD-L1 Expressing Hematopoietic Stem Cells for Type 1 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for type 1 diabetes are nonspecific and fail to effectively re-establish tolerance to islet auto-antigens, leading to inadequate treatment outcomes.
Innovation Solution
Genetically engineered or pharmacologically modulated hematopoietic stem and progenitor cells (HSPCs) are produced to overexpress PD-L1, which are then administered to inhibit autoimmune responses and restore tolerance by targeting a specific immune checkpoint defect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broadly immunosuppressive therapies are used to treat type 1 diabetes, then immune response is suppressed, but the treatment lacks specificity and fails to re-establish tolerance to islet auto-antigens
Solution Approach 1:
The patent applies local quality by modifying HSPCs to specifically overexpress PD-L1, creating a localized immunomodulatory effect at the site of autoimmune attack (pancreas/islets) rather than systemic immunosuppression. This targeted approach restores tolerance to islet auto-antigens without broadly suppressing the entire immune system.
Solution Approach 2:
The patent changes the expression parameter of PD-L1 on HSPCs through genetic modification or pharmacological modulation. By increasing PD-L1 expression levels specifically on these cells, the therapy achieves selective immunoregulation that addresses the specific defect in T1D pathogenesis without causing broad immunosuppression.
2Reliability
If HSPCs are genetically engineered to overexpress PD-L1, then autoimmune response is inhibited and diabetes is reverted, but the cellular defect in PD-L1 expression must be identified and targeted
Solution Approach 1:
The patent applies preliminary action by first identifying the PD-L1 expression defect in HSPCs from T1D patients through transcriptomic profiling and flow cytometry, then preemptively correcting this defect through genetic engineering or pharmacological modulation before transplantation, ensuring the modified cells can effectively inhibit autoimmune responses.
Solution Approach 2:
The patent substitutes mechanical/direct observation methods with molecular biology techniques (transcriptomic profiling, flow cytometry, genetic engineering) to detect and correct the PD-L1 defect. This allows precise identification and modification of the cellular defect that would be undetectable through conventional methods.
3Productivity
If miRNA expression is modulated to control PD-L1, then PD-L1+ HSCs are produced, but viral vectors and oligonucleotide agents are required for delivery
Solution Approach 1:
The patent uses viral vectors and oligonucleotide agents as intermediary carriers to deliver miRNA modulation sequences into HSCs. These intermediaries enable precise control of PD-L1 expression through miRNA pathways without requiring direct genetic modification of the PD-L1 gene itself, simplifying the overall approach while achieving the desired effect.
Solution Approach 2:
The patent introduces exogenous copies of miRNA sequences or antisense oligonucleotides into HSCs to mimic or inhibit endogenous miRNA function. This copying approach allows control of PD-L1 expression through RNA-level regulation rather than permanent genomic integration, reducing complexity and safety concerns.
Data Source
AI summary
Described herein are methods and compositions for producing modified, PD-L1 expressing hematopoietic stem cells, and uses thereof. Aspects of the invention relate to modulating the expression of micro RNA that controls the expression of PD-L1 in the hematopoietic stem cell. Methods for modulating the expression of micro RNA include, e.g., introducing to the cell a nucleic acid encoding a given micro RNA, or an agent that inhibits a given micro RNA.